Abstract:

Angiogenesis is the key to the progress and prognosis of diabetic retinopathy (DR). So far,  published studies have shown lots of antiangiogenic drugs. Some of these drugs,  such as glucocorticoid and vascular endothelial growth factor inhibitors,  has been widely applied in clinic,  inhibiting neovascularization in different degrees. And the others has been still in animal or clinical trials. Besides insulin-like growth factor binding protein 3 and angiostatin controlling angiogenesis directly,  leucine-rich alpha-2-glycoprotein 1 and connexin Shc could participate in the process of neovascularization,  to become the new therapeutic targets of antiangiogensis.